First Cellular Therapy to Treat Patients with Type 1 Diabetes has been approved by FDA.
It is the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes.
“Severe hypoglycemia is a dangerous condition that can lead to injuries resulting from loss of consciousness or seizures,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval, the first-ever cell therapy to treat patients with type 1 diabetes, provides individuals living with type 1 diabetes and recurrent severe hypoglycemia an additional treatment option to help achieve target blood glucose levels.”
Visit FDA.gov for the full press release #diabetes #diabetessupport
Come and meet us at Expopharm 2023! 27 -30 September in DÜSSELDORF. Our colleagues Luca Schincaglia and Marco Ferrario will